Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Press Release".
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums Drugs and Pharmaceuticals reported Q4 FY26 operating revenue of ₹1,158 crore, up 9.7% YoY, with adjusted PAT surging 135% to ₹83 crore from ₹35 crore in Q4 FY25. Full-year FY26 revenue stood at ₹4,359 crore, growing 5.9% YoY, with adjusted EBITDA at ₹522 crore (up 13.3%) and adjusted PAT at ₹276 crore (up 27.3%). EBITDA margin expanded to 13.1% in Q4 from 8.9% YoY, reflecting improved operational efficiency. The CDMO segment drove growth with revenue of ₹952 crore and EBITDA margin improvement to 14.4%. The board recommended a final dividend of ₹1 per share plus a special dividend of ₹2 per share. Key international milestones include first commercial supply to Europe, EU GMP certifications, UK MHRA approval for Rivaroxaban, and Brazil ANVISA certification for the injectable plant.
Strong profitability growth with margins expanding significantly signals operational efficiency gains. The dividend payout, including a special dividend, signals management confidence in cash generation. International regulatory approvals strengthen the company's regulated market ambitions.